T-Cell
Entity.
- Evidence
- 127 documents · 41 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 1 Jan 2026, last seen 7 Oct 2026
- Measured
- 14% of mentions say something specific about it; the rest only name it
- As of
- 8 Oct 2026
Where this comes from
- Frontiers Precision Oncology · 2026-10-07 · Targeting NOTCH-immune crosstalk in gliomas: from mechanisms to therapeutics (opens the source in a new tab)
- The ASCO Post · 2026-10-05 · Relapsed or Refractory SCLC Phase I Study of Novel CAR T-Cell Therapy (opens the source in a new tab)
- Pulse 2.0 · 2026-10-03 · Novartis Signs Up To $7.8 Billion Licensing Deal With Abogen For mRNA-Encoded T-Cell Engager (opens the source in a new tab)
- J Immunother Cancer · 2026-10-01 · Propionate promotes CD8+ T-cell infiltration and enhances immunotherapy efficacy in colorectal cancer. (opens the source in a new tab)
- bioRxiv Cancer Biology · 2026-09-28 · Spatial immune profiling reveals lymphocyte confinement to myeloid-mesenchymal niches and heterogeneous therapeutic T-cell opportunity in pediatric ependymoma (opens the source in a new tab)
- Br J Pharmacol · 2026-09-28 · Low-dose antiangiogenic multikinase inhibitor AL3810 synergizes with PD-1 blockade by reducing CSF1-driven MHC-IIint tumour-associated macrophages to optimize TIM-3+ CD8… (opens the source in a new tab)
- European Medical Journal · 2026-09-24 · Fatal Inflammatory Risks Associated with CAR T-Cell Therapy (opens the source in a new tab)
- BMJ Oncol · 2026-09-21 · Cytotoxic T-cell exhaustion analyses by in situ single-cell immunofluorescence in relation to colorectal cancer patient age, tissue bacteria and mortality. (opens the source in a new tab)
- J Immunother Cancer · 2026-09-12 · Epigenetic plus cytokine therapy induces stem-like CD8+ T-cell reservoirs and intratumoral immune niches to overcome anti-PD-1 resistance. (opens the source in a new tab)
- Fierce Biotech · 2026-09-03 · AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial (opens the source in a new tab)
What is claimed about it
- Reported by two: Reported by two sources that did not copy each other.
- Single source: Reported by one source so far.
- Integrated spatial and single-cell transcriptomics uncover IFI6⁺ regulatory T-cells and SPP1⁺ macrophages immunosuppressive niches in colorectal cancer. Reported by two · first reported 6 Oct 2026
- Propionate promotes CD8+ T-cell infiltration and enhances immunotherapy efficacy in colorectal cancer Single source · first reported 1 Oct 2026